IDT launches oPools Oligo Pools
The longest, highest fidelity, and ready-to-use custom oligo pools on the market.
Integrated DNA Technologies (IDT) has launched oPools Oligo Pools – ready-to-use pools of high-quality DNA oligos up to 350 nucleotides long. Thanks to its industry-leading proprietary manufacturing processes and 30 years of dedication to exceptional quality products, IDT is able to provide oligo pools unparalleled in uniformity at yields that accelerate experiments by eliminating time-consuming and bias-producing PCR amplification steps required by other commercially available pools.
Pooled oligos are widely used in high-throughput workflows in synthetic biology, diagnostic development, and drug discovery. For optimum performance, such pools must be uniformly comprised of full-length oligos of the highest possible fidelity (oligos of correct sequence and length). IDT’s proprietary manufacturing platform produces long oligos more accurately, rapidly, and reliably than any other DNA synthesis platform, enabling timely delivery of the highest fidelity and most uniform oligonucleotide pools available.
oPools' low error rate of less than 1 in 2000 nucleotides, coupled with high per oligo yields, allow researchers to proceed immediately and confidently into their downstream workflows for projects including CRISPR library construction, protein screening, and gene assembly. For synthetic biologists, quick access to affordable, high-quality oligo pools that can go directly into their pipeline without the hands-on time required for PCR amplification allows for faster and more impactful “Design, Build, Test” cycles so critical to discovery.
Early adopters of the product offering have benefitted from the high-quality oPools for their applications, including ArcherDX, a molecular technology company dedicated to developing breakthrough solutions that advance personalized genomic medicine. Josh Stahl, Chief Scientific Officer of ArcherDX, commented: “ArcherDX evaluated several comparable product offerings from array-based providers, and the oPools from IDT were the best solution available to deliver the performance, speed, and ease-of-use necessary to meet our exacting requirements.”
Unlike suppliers that opt for array or silicon chip-based batch synthesis, IDT employs a unique, solid-support manufacturing platform that individually synthesizes every oligo. This delivers the highest percentage of full-length DNA in the industry. IDT’s manufacturing approach also ensures that each species of oligo is represented and at greater uniformity in the resulting pool allowing for a more complete experiment downstream. For IDT, 95% of sequences in oPools Oligo Pools are represented within 1.5x of the mean, compared to 90% within 4x of the mean for a comparative supplier.
Trey Martin, President of IDT, commented: “IDT has historically avoided the traditional pools market due to our capacity being fully booked. Two years into our 6th-generation synthesis platform, we have alleviated all capacity concerns and are thrilled to offer our unique take on oligo pools. They leverage the ultra-high fidelity of IDT synthesis to give heretofore unobtainable experimental results from the traditional microarray-driven approach. We have been in beta testing for 6 months and customers are delighted with the results. Our pool deliveries are in picomoles, eliminating the need to do any pre-amplification or other pre-work before the pool can be used. With lengths up to 350 bases and error rates below one per 2kB, these are the same oligos that IDT relies on for our own high-throughput gene assembly processes.”
IDT’s oPools are ready-to-run, affordable pools of customized single-stranded DNA sequences between 40-350 nt in length. There is no minimum order, pools are compatible with downstream cloning methods, and have a short turnaround time of just four to seven business days from ordering to delivery. oPools™ unparalleled concentration, uniformity, and low error rates assure high target specificity and provide researchers with the utmost confidence in results.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance